Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp. -- Ignore unavailable to you. Want to Upgrade?

To: esammee who wrote (2960)	8/1/2006 11:46:26 PM
From: esammee	Read Replies (2) \| Respond to of 3576

In May we published with our collaborator, Dr. Brittney-Shay Herbert at Indiana University the second study of 163L on breast cancer. And here the object of the exercise was to demonstrate that all known forms of breast cancer, including mutations in epidermal growth factor, HER2, mutations in P53 status, mutations in the estrogen receptor, BRCA1 mutants and doxorubicin resistant lines – all of those breast cancer lines in vitro were sensitive to GRN163L, again demonstrating the wide range of tumor types that the drug is active against. She then went on to do in vivo studies which also showed the drug to be very active in inhibiting the growth of primary tumors, again of breast cancer type, in that 5 of 10 animals were completely cured with no evidence of breast cancer at all and a dramatic decrease in the ability of the cells to metastasize – very similar to the earlier presentation from the Shay lab on the metastatic inhibitory effect of the drug in lung cancer.